Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.

Market Analysis and Insights: Global Biosimilar Monoclonal Antibodies Market
The global Biosimilar Monoclonal Antibodies market is valued at US$ 4574.3 million in 2019. The market size will reach US$ 25770 million by the end of 2026, growing at a CAGR of 27.7% during 2021-2026.

Global Biosimilar Monoclonal Antibodies Scope and Market Size
Biosimilar Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other

Segment by Application
Oncology
Autoimmune Disease
Other

By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia